IPS results suggested that the patients with low-risk scores were sensitive to anti-CTLA-4, -PD-1, and -CTLA-4/PD-1, which suggested the potential role of immunotherapy in CM patients (Figure 8C). This evidence concerns the gene PDCD1 and cutaneous mastocytosis.